scholarly journals Adenovirus-mediated delivery of Sema3A alleviates rheumatoid arthritis in a serum-transfer induced mouse model

Oncotarget ◽  
2017 ◽  
Vol 8 (39) ◽  
pp. 66270-66280 ◽  
Author(s):  
Yue Teng ◽  
Zhanhai Yin ◽  
Jing Li ◽  
Kun Li ◽  
Xu Li ◽  
...  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Bonnie J. B. Lewis ◽  
Jade Ville ◽  
Megan Blacquiere ◽  
Selena Cen ◽  
Rolf Spirig ◽  
...  

Abstract Background High-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases; however, there are challenges associated with product production, availability, access and efficacy. These challenges have provided incentives to develop a human recombinant Fc as a more potent alternative to IVIg and SCIg for the treatment of autoimmune diseases. Recently, a recombinant human IgG1 Fc hexamer (Fc-μTP-L309C) was shown to be more efficacious than IVIg in a variety of autoimmune mouse models. We have now examined its efficacy compared to IVIg and SCIg in the K/BxN mouse model of endogenous, chronic rheumatoid arthritis (RA). Result Using the serum-transfer K/BxN model and the endogenous autoimmune model, amelioration of the arthritis was achieved. Effective treatment required high and frequent doses of IVIg, SCIg and Fc-μTP-L309C. However, Fc-μTP-L309C was efficacious at 10-fold lower doses that IVIg/SCIg. Also, arthritis could be prevented when Fc-μTP-L309C was given prior to onset of the arthritis in both the endogenous model and in the serum transfer model. Conclusions Our results show that Fc-μTP-L309C is a powerful treatment for the prevention and amelioration of severe, chronic arthritis in a true autoimmune mouse model of RA. Thus, the K/BxN endogenous arthritis model should be useful for testing potential therapeutics for RA. Our findings provide rationale for further examination of the treatment efficacy of immunoglobulin-based therapeutics in rheumatoid arthritis.


2019 ◽  
Vol 23 (10) ◽  
pp. 7043-7053
Author(s):  
Yasuhiro Terasaki ◽  
Mika Terasaki ◽  
Satoshi Kanazawa ◽  
Nariaki Kokuho ◽  
Hirokazu Urushiyama ◽  
...  

Nanomedicine ◽  
2011 ◽  
Vol 6 (10) ◽  
pp. 1669-1682 ◽  
Author(s):  
Robert I Scheinman ◽  
Ruchit Trivedi ◽  
Sam Vermillion ◽  
Uday B Kompella

2012 ◽  
Vol 278 (1-2) ◽  
pp. 158-165 ◽  
Author(s):  
Tamás Kobezda ◽  
Sheida Ghassemi-Nejad ◽  
Tibor T. Glant ◽  
Katalin Mikecz

2015 ◽  
Vol 45 ◽  
pp. 50-59 ◽  
Author(s):  
Éva Borbély ◽  
Bálint Botz ◽  
Kata Bölcskei ◽  
Tibor Kenyér ◽  
László Kereskai ◽  
...  

Autoimmunity ◽  
1994 ◽  
Vol 17 (2) ◽  
pp. 157-163 ◽  
Author(s):  
John S Axford ◽  
Azita Alavi ◽  
Angela Bond ◽  
Frank C Hay

Sign in / Sign up

Export Citation Format

Share Document